Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 3/2023

23.05.2023 | Original Article

Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma

verfasst von: Xucai Zheng, Jing Wang, Tingbo Ye, Weifang Tang, Xikong Pan, Shengying Wang, Jianjun Liu

Erschienen in: Endocrine | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Anaplastic thyroid carcinoma (ATC) is one of the most lethal malignancies with no effective treatment. In this study, we investigated the efficacy and safety of anlotinib-based chemotherapy as first-line therapy for ATC.

Methods

Locally advanced or metastatic (LA/M) ATC patients who never received antitumor treatment of any sort were eligible for this study. The patients received 2–6 cycles anlotinib12mg on days 1–14 per 21 days. Chemotherapy regimens consisted of paclitaxel, capecitabine, or paclitaxel plus carboplatin/capecitabine. The end points including Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), and Disease Specification Survival (DCS) were analyzed.

Results

A total of 25 patients were enrolled. 1 patient achieved a Complete Response (CR) and 14 patients achieved Partial Response (PR). The best ORR was 60.0%, and the DCR was 88.0%. The median PFS was 25.1 weeks, and the median DCS was 96.0 weeks. Approximately 56% (14 patients) had at least one Adverse Event (AE) of any grade. Most AEs were well tolerated. The most common AEs was palmar–plantar erythrodysesthesia syndrome (28.0%).

Conclusions

Anlotinib-based chemotherapy as first-line therapy is a safe and effective intervention for the treatment of LA/M ATC patients.
Literatur
1.
R.C. Smallridge, J.A. Copland, Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. (R. Coll. Radio.) 22, 486–497 (2010)CrossRef
2.
S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 83, 2638–2648 (1998)PubMedCrossRef
3.
H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. Jama 317, 1338–1348 (2017)PubMedPubMedCentralCrossRef
4.
E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103, 1330–1335 (2005)PubMedCrossRef
5.
M.L. Carcangiu, T. Steeper, G. Zampi, J. Rosai, Anaplastic thyroid carcinoma. A study of 70 cases. Am. J. Clin. Pathol. 83, 135–158 (1985)PubMedCrossRef
6.
J. Akaishi, K. Sugino, W. Kitagawa, M. Nagahama, K. Kameyama et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21, 1183–1189 (2011)PubMedCrossRef
7.
R.C. Smallridge, K.B. Ain, S.L. Asa, K.C. Bible, J.D. Brierley et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104–1139 (2012)PubMedCrossRef
8.
B. Salehian, S.Y. Liem, H. Mojazi Amiri, E. Maghami, Clinical trials in management of anaplastic thyroid carcinoma; progressions and set backs: a systematic review. Int J. Endocrinol. Metab. 17, e67759 (2019)PubMedPubMedCentral
9.
E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644–660 (2017)PubMedCrossRef
10.
M.K. Gule, Y. Chen, D. Sano, M.J. Frederick, G. Zhou et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin. Cancer Res 17, 2281–2291 (2011)PubMedPubMedCentralCrossRef
11.
K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31, 337–386 (2021)PubMedPubMedCentralCrossRef
12.
G. Shen, F. Zheng, D. Ren, F. Du, Q. Dong et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11, 120 (2018)PubMedPubMedCentralCrossRef
13.
14.
Q. Xu, J. Wang, Y. Sun, Y. Lin, J. Liu et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J. Clin. Oncol. 40, 1795–1805 (2022)PubMedPubMedCentralCrossRef
15.
B. Han, K. Li, Q. Wang, L. Zhang, J. Shi et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4, 1569–1575 (2018)PubMedPubMedCentralCrossRef
16.
Z.M. Wang, R.Y. Zhuang, X. Guo, C.L. Zhang, Y. You et al. Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial. Clin. Cancer Res. 28, 5290–5296 (2022).PubMedCrossRef
17.
Y. Sun, F. Du, M. Gao, Q. Ji, Z. Li et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer. Thyroid 28, 1455–1461 (2018)PubMedCrossRef
18.
I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052–1066 (2016)PubMedPubMedCentralCrossRef
19.
H. Duan, Y. Li, P. Hu, J. Gao, J. Ying et al. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology 75, 890–899 (2019)PubMedCrossRef
20.
N. Pozdeyev, L.M. Gay, E.S. Sokol, R. Hartmaier, K.E. Deaver et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res. 24, 3059–3068 (2018)PubMedPubMedCentralCrossRef
21.
X. Shi, R. Liu, S. Qu, G. Zhu, J. Bishop et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 100, E632–637 (2015)PubMedPubMedCentralCrossRef
22.
K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med 367, 1694–1703 (2012)PubMedPubMedCentralCrossRef
23.
S.G. Waguespack, A. Drilon, J.J. Lin, M.S. Brose, R. McDermott et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur. J. Endocrinol. 186, 631–643 (2022)PubMedPubMedCentralCrossRef
24.
I. Damásio, J. Simões-Pereira, S. Donato, M. Horta, B.M. Cavaco et al. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. Eur. Thyroid J. 12, e220179 (2022)PubMedPubMedCentral
25.
D. Hanahan, Hallmarks of cancer: new dimensions. Cancer Disco. 12, 31–46 (2022)CrossRef
26.
27.
28.
M. Shibuya, Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2, 1097–1105 (2011)PubMedPubMedCentralCrossRef
29.
K. Sato, Vascular endothelial growth factors and thyroid disorders. Endocr. J. 48, 635–646 (2001)PubMedCrossRef
30.
R.K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987–989 (2001)PubMedCrossRef
31.
R.T. Kloos, M.D. Ringel, M.V. Knopp, N.C. Hall, M. King et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27, 1675–1684 (2009)PubMedPubMedCentralCrossRef
32.
V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26, 4714–4719 (2008)PubMedPubMedCentralCrossRef
33.
P. Savvides, G. Nagaiah, P. Lavertu, P. Fu, J.J. Wright et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23, 600–604 (2013)PubMedPubMedCentralCrossRef
34.
Y. Ito, N. Onoda, K.I. Ito, I. Sugitani, S. Takahashi et al. Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 27, 1142–1148 (2017)PubMedPubMedCentralCrossRef
35.
E.J. Sherman, L.A. Dunn, A.L. Ho, S.S. Baxi, R.A. Ghossein et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer 123, 4114–4121 (2017)PubMedCrossRef
36.
O. Tohyama, J. Matsui, K. Kodama, N. Hata-Sugi, T. Kimura et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J. Thyroid Res. 2014, 638747 (2014)PubMedPubMedCentralCrossRef
37.
S. Takahashi, N. Kiyota, T. Yamazaki, N. Chayahara, K. Nakano et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 15, 717–726 (2019)PubMedCrossRef
38.
A. Ravaud, C. de la Fouchardière, P. Caron, A. Doussau, C. Do Cao et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur. J. Cancer 76, 110–117 (2017)PubMedCrossRef
39.
C. Xie, X. Wan, H. Quan, M. Zheng, L. Fu et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 109, 1207–1219 (2018)PubMedPubMedCentralCrossRef
40.
X. Ruan, X. Shi, Q. Dong, Y. Yu, X. Hou et al. Antitumor effects of anlotinib in thyroid cancer. Endocr. Relat. Cancer 26, 153–164 (2019)PubMedCrossRef
41.
N.S. Huang, W.J. Wei, J. Xiang, J.Y. Chen, Q. Guan et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase II clinical trial. Thyroid 31, 1808–1813 (2021)PubMedCrossRef
42.
R.O. Wein, R.S. Weber, Anaplastic thyroid carcinoma: palliation or treatment? Curr. Opin. Otolaryngol. Head. Neck Surg. 19, 113–118 (2011)PubMedCrossRef
43.
Metadaten
Titel
Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma
verfasst von
Xucai Zheng
Jing Wang
Tingbo Ye
Weifang Tang
Xikong Pan
Shengying Wang
Jianjun Liu
Publikationsdatum
23.05.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2023
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03390-y

Weitere Artikel der Ausgabe 3/2023

Endocrine 3/2023 Zur Ausgabe

Viewpoint

Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?

Original Article

Increased prevalence of nodular thyroid disease in patients with Klinefelter syndrome

Review

Parathyroid carcinoma: molecular therapeutic targets

Brief report

Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination

Original Article

Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model

Original Article

Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise